Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 CAD | +1.94% | +1.94% | -22.22% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.22% | 106M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- NGEN Stock
- News NervGen Pharma Corp.
- NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer